Version 1
: Received: 16 June 2020 / Approved: 18 June 2020 / Online: 18 June 2020 (12:43:43 CEST)
How to cite:
Dharavath, R.N.; Dutt, M.; Kumar, S.; Badyal, P.; Rawat, N.; Kaur, T.; Sharma, S.; Bishnoi, M.; Chopra, K. Repurposing of FDA Approved Drugs as COVID-19 Therapeutics: Safety Concerns and Contraindications of Drugs in Clinical Trials. Preprints2020, 2020060232 (doi: 10.20944/preprints202006.0232.v1).
Dharavath, R.N.; Dutt, M.; Kumar, S.; Badyal, P.; Rawat, N.; Kaur, T.; Sharma, S.; Bishnoi, M.; Chopra, K. Repurposing of FDA Approved Drugs as COVID-19 Therapeutics: Safety Concerns and Contraindications of Drugs in Clinical Trials. Preprints 2020, 2020060232 (doi: 10.20944/preprints202006.0232.v1).
Cite as:
Dharavath, R.N.; Dutt, M.; Kumar, S.; Badyal, P.; Rawat, N.; Kaur, T.; Sharma, S.; Bishnoi, M.; Chopra, K. Repurposing of FDA Approved Drugs as COVID-19 Therapeutics: Safety Concerns and Contraindications of Drugs in Clinical Trials. Preprints2020, 2020060232 (doi: 10.20944/preprints202006.0232.v1).
Dharavath, R.N.; Dutt, M.; Kumar, S.; Badyal, P.; Rawat, N.; Kaur, T.; Sharma, S.; Bishnoi, M.; Chopra, K. Repurposing of FDA Approved Drugs as COVID-19 Therapeutics: Safety Concerns and Contraindications of Drugs in Clinical Trials. Preprints 2020, 2020060232 (doi: 10.20944/preprints202006.0232.v1).
Abstract
Coronavirus disease (COVID-19) is the current global public health threat with no specific, effective, and approved treatment available till date. The outbreak of COVID-19 has led the world into an unimagined and uncertain situation by disrupting the economies, claiming human lives, and leaving many into secondary mental health problems. As per the latest WHO report, approximately 8.2 million people are infected, and nearly 0.44 million lives are lost to COVID. The infection has spread to over 200 countries and territories around the world. The world is in search of efficient diagnostics and therapeutics, including vaccines, biologics and drugs. With the rapid increase in rates of infection and time constraints, drug repurposing seems to be a potential and viable option to find the promising anti-COVID therapeutics. In the wake of a rapid increase in the number of clinical trials involving drugs for repurposing, we aim to provide information on the safety concerns related to the drugs currently investigated in trials. This review also highlights the possible mechanisms of actions, adverse drug reactions, and contraindications of the drugs under repurposing evaluation.
Subject Areas
Adverse drug reactions; Anti-COVID drugs; Coronavirus; Drug repurposing; Drug toxicity; Pharmacotherapy
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Ravinder Naik Dharavath
*
,
Commenter: Ritu Sharma
The commenter has declared there is no conflict of interests.